- Home
- RNR vs EXEL Comparison
RNR vs EXEL Comparison
Compare RNR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNR | EXEL |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 11.1B |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RNR | EXEL |
|---|---|---|
| Price | $266.10 | $44.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 24 |
| Target Price | ★ $291.73 | $44.73 |
| AVG Volume (30 Days) | 387.6K | ★ 2.5M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | ★ 34.70 | 2.38 |
| Revenue | ★ $12,214,870,000.00 | $2,288,218,000.00 |
| Revenue This Year | N/A | $9.14 |
| Revenue Next Year | N/A | $12.51 |
| P/E Ratio | ★ $7.63 | $18.67 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $219.00 | $31.90 |
| 52 Week High | $290.78 | $49.62 |
Technical Indicators
Market Signals| Indicator | RNR | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 63.52 |
| Support Level | $261.38 | $43.00 |
| Resistance Level | $263.87 | $44.79 |
| Average True Range (ATR) | 5.15 | 1.03 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 64.18 | 83.48 |
Price Performance
Historical ComparisonAbout RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.